What makes an emerging technology bold enough and a founder exceptional enough to justify taking an early-stage risk? In this episode of The Business of Neurotech, Adam Fraser sits down with Matias Serebrinsky, Founding Partner at PsyMed Ventures, a specialist venture capital fund investing in frontier brain and mental health technologies. Matias brings a dual perspective as both a former startup founder and an early-stage investor who previously supported AI companies during a pivotal period in the industry’s growth. In this conversation, he reflects on how breakthrough technologies move from research labs into real-world products and what it takes for scientific drive to become a venture-scale company. They also discuss the evolution of neurotechnology as an investment category, the realities of backing high-risk frontier science, and how PsyMed assesses early-stage opportunities across brain-computer interfaces, neuromodulation, mental health innovation and more. Tune in for an investor’s view of the people and technologies driving frontier neuro forward.

Key Points From This Episode:

• [01:15] Explore Matias’ journey from startup founder and NVIDIA to neuro investing.
• [05:37] Uncover the three qualities PsyMed looks for in an early-stage investment.
• [06:54] Explore Matias’ broad definition of neurotech and the market behind it.
• [08:30] He shares PsyMed’s approach to investing early and supporting founders.
• [12:55] Whether specialist and generalist funds will grow as more investors join.
• [15:35] Consider what major exits could mean for neurotech’s investment appeal.
• [18:54] Learn which opportunities are currently capturing PsyMed’s attention.
• [22:18] Hear about a BCI company taking a different path to developing neurotech.
• [28:34] Discover the role capital plays in turning science into a successful company.
• [30:58] Unpack the different hardware approaches to neuromodulation.
• [34:15] Understand what changes when a wellness product enters medical territory.
• [36:28] Matias’ advice for researchers considering the startup journey.

Links Mentioned in Today’s Episode:

Matias Serebrinsky on LinkedIn

PsyMed Ventures

PsyMed Ventures on Substack

Business Trip Podcast

‘The State of Frontier Neuro’

Motif

Adam Fraser on LinkedIn

Omniscient Neurotechnology

The Business of Neurotech Podcast

How do you turn promising neurotechnology into solutions that can actually work inside healthcare systems? In this episode of The Business of Neurotech Podcast, Adam Fraser is joined by Richard Mulry, President and CEO of Northwell Holdings, the for-profit venture investment arm of Northwell Health, to explore what it takes to identify, invest in, and scale innovation in clinical care. Richard explains why Northwell prefers to invest in companies it would use itself, and how clinical evidence, workflow integration, and strong partnerships shape every investment decision. The conversation explores the unique opportunities and challenges of neurotechnology, from brain-computer interfaces (BCIs) and neurorehabilitation to AI-enabled platforms and bioelectronic medicine. Richard also shares why solving meaningful clinical problems matters more than following investment trends, how strategic healthcare investors can help companies prove real-world value, and what founders should know about working with strategic investors. Listen in for an insightful discussion on what it takes to bring neurotechnology from concept to clinical impact!

Key Points From This Episode:

• [01:28] Richard’s career in healthcare and his path to Northwell Holdings.
• [04:32] Background on Northwell and its approach to healthcare innovation.
• [07:15] Discover Northwell's investment process and selection criteria.
• [11:25] Why Northwell prefers to invest in companies it would use itself.
• [12:30] Find out how Northwell complements traditional venture capital investors.
• [16:46] Understand Richard’s perspective on the neurotech market.
• [19:29] Hear why Northwell invested in Cognixion and its evolving platform.
• [21:43] Explore Northwell’s view of invasive versus non-invasive BCIs.
• [26:36] Learn about Northwell’s latest neurotech investments.
• [31:31] Understand how Northwell supports companies through FDA and reimbursement.
• [32:50] Discover how AI is reshaping healthcare operations and medtech.
• [37:03] Richard’s advice for founders seeking strategic investors.
• [39:33] Final takeaways and how to connect with Northwell Holdings.

Links Mentioned in Today’s Episode:

Richard Mulry on LinkedIn

Northwell Holdings

Northwell Holdings on LinkedIn

Northwell Health

Northwell Health on LinkedIn

Feinstein Institutes for Medical Research | Northwell Health

Cognixion

Neuvotion

Spark Biomedical

OhmBody

SetPoint Medical

Adam Fraser on LinkedIn

Omniscient Neurotechnology

The Business of Neurotech Podcast

What does it take to build a BCI company around better hardware, stronger data, and a long-term view of how the brain will be decoded? In this episode of The Business of Neurotech, host Adam Fraser is joined by Nicolas Vachicouras, CEO and co-founder of Neurosoft Bioelectronics, to discuss his path from microelectronics and nanotechnology into the BCI space, and how Neurosoft is developing soft, stretchable electrodes designed to sit on the brain surface rather than penetrate it. Adam and Nicolas discuss the technical and commercial thinking behind Neurosoft’s strategy, how the company has moved from early academic work to first-in-human studies, and why platform thinking now matters more than pursuing a single indication. They also discuss fundraising in Europe versus the US, why BCI still needs high-quality invasive data to unlock future breakthroughs, how the partnership with Science Corp fits into the wider BCI value chain, and why Nicolas believes the field will likely support several major players over time. Tune in now!

Key Points From This Episode:

• [01:25] Nicolas’ backstory and how his studies led him into BCI.
• [03:17] See how Nicolas first started thinking about commercialising neurotechnology.
• [05:56] Explore what Neurosoft is building and the core idea behind its approach to BCI.
• [07:43] Understand how Neurosoft’s approach differs from typical BCI technology.
• [09:17] The different levels of invasiveness in BCI and how this impacts data quality.
• [11:38] Neurosoft’s progress and how the roadmap to clinical trials is taking shape.
• [15:15] Learn how Neurosoft’s focus has evolved from tinnitus towards a broader strategy.
• [17:40] Find out whether mental health is part of Neurosoft’s long-term plan.
• [18:52] Unpack Neurosoft’s funding journey and what Nicolas has learnt along the way.
• [21:19] Discover why Neurosoft is starting with the US market, instead of Europe.
• [22:28] Why funding in a market where competitors have more capital is not an issue.
• [24:00] Examine how the partnership with Science Corp fits into Neurosoft’s long-term goals.
• [28:27] How BCI fits into the broader neurotech ecosystem and the future market of BCI.
• [30:59] Uncover why reimbursement remains such an important challenge for BCI.
• [32:39] Hear how Nicolas thinks about building a team for a long-term goal.
• [36:14] Final takeaways and how to connect with Nicolas and Neurosoft Bioelectronics.

Links Mentioned in Today’s Episode:

Nicolas Vachicouras

Nicolas Vachicouras on LinkedIn

Neurosoft Bioelectronics

Science Corp

Adam Fraser on LinkedIn

Omniscient Neurotechnology

The Business of Neurotech Podcast